Cultured pressure ulcer fibroblasts show replicative senescence with elevated production of plasmin, plasminogen activator inhibitor-1, and transforming growth factor-β1

Wound Repair and Regeneration

Volumn 13, Issue 1, 2005, Pages 76-83

  Vande Berg, Jerry S ^a,d   Rose, Michael A ^a   Haywood Reid, Patricia L ^a   Rudolph, Ross ^a,b   Payne, Wyatt G ^c   Robson, Martin C ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS CLINIC   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d Research Service   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL CULTURE; CELL DIVISION; CLINICAL ARTICLE; DECUBITUS; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; INFLAMMATION; LIFESPAN; PRIORITY JOURNAL; SENESCENCE; SKIN FIBROBLAST;

BETA-GALACTOSIDASE; CELL AGING; CELLS, CULTURED; CHRONIC DISEASE; FIBROBLASTS; HUMANS; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRESSURE ULCER; TRANSFORMING GROWTH FACTOR BETA;

EID: 13844294020     PISSN: 10671927     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1067-1927.2005.130110.x     Document Type: Article

References (36)

1. Kucukcelebi A, Hui PS, Sahara K. The effect of interleukin-1β on the inhibition of contraction of excisional wounds caused by bacterial contamination. Surg Forum 1992;43:715-6.
2. Mustoe TA, Cutler NR, Allman RM, Goode PS, Deuel TF, Prause JA, Bear M, Serdar CM, Pierce GF. A phase II study to evaluate recombinant PDGF-BB in the treatment stage III/IV pressure ulcers. Arch Surg 1994;129:213-9.
3. Pierce GF, Tarpley JE, Allman RM, Goode PS, Serdar CM, Morris B, Mustoe TA, Vande Berg JS. Tissue repair processes in healing chronic pressure ulcers treated with recombinant platelet derived growth factor BB. Am J Pathol 1994;145:1399-410.
4. Rees RS, Robson MC, Smiell JM, Perry BH. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study. Wound Rep Reg 1999;7:141-7.
5. Robson MC, Phillips LG, Thomason A, Robson LF, Pierce GF. Platelet derived growth factor-BB in chronic pressure ulcers. Lancet 1992;339:23-5.
6. Robson MC, Abdullah A, Burns BF, Phillips LG, Garrison L, Cowan W, Hill D, Vande Berg JS, Robson LE, Scheeler S. Safety and effect of the topical recombinant human interleukin-1β in the management of pressure sores. Wound Rep Reg 1994;2:177-81.
7. Mast BA, Schultz GS. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Rep Reg 1996;4:411-20.
8. Seah CC, Phillips T. Modulation of cell cycle regulatory proteins by chronic wound fluid. Wounds 1996;13:136-42.
9. Tarnuzzer RW, Schultz GS. Biochemical analysis of acute and chronic wound environments. Wound Rep Reg 1996;4:321-5.
10. Yager DR, Chen SM, Ward SI, Olutoye OO, Diegelmann RF, Cohen IK. Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of protease inhibitors. Wound Rep Reg 1997;5:23-32.
11. Yager DR, Nwomeh BC. The proteolytic environment of chronic wounds. Wound Rep Reg 1999;7:433-41.
12. Agren MS, Steenfos HH, Dabelsteen S, Hansen JB, Dabelsteen E. Proliferation and mitogenic respone to PDGF-BB of fibroblasts isolated from chronic venous leg ulcers is ulcer-age dependent. J Invest Dermatol 1999;112:463-9.
13. Mendez MV, Stanley A, Park HY, Shon K, Phillips T, Menzoian JO. Fibroblasts cultured from venous ulcers display cellular characteristics of senescence. J Vasc Surg 1998;28:876-83.
14. Vande Berg JS, Rudolph R, Hollan C, Haywood-Reid PL. Fibroblast senescence in pressure ulcers. Wound Rep Reg 1998;6:38-49.
15. Campisi J. Aging and cancer. The double-edged sword of replicative senescence. J Am Geriatr Soc 1998;45:482-8.
16. Campisi J. The role of cellular senescence in skin aging. J Invest Dermatol Symp Proc 1998;3:1-5.
17. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9:1149-63.
18. Vande Berg JS, Smith PD, Haywood-Reid PL, Munson AB, Soules KA, Robson MC. Dynamic forces in the cell cycle affecting fibroblasts in pressure ulcers. Wound Rep Reg 1995;9:19-27.
19. Kelman Z. PCNA: structure, functions and interactions. Oncogene 1997;14:629-40.
20. Vande Berg JS, Smith PD, Haywood-Reid PL, Munson AB, Bradley NR, Robson MC. Influence of single and sequential cytokine therapy on the cell cycle of pressure ulcer fibroblasts. J App Res 2002;2:11-.
21. Dell'Orco RT, Mertens JG, Kruse PF Jr. Doubling potential, calendar time, and donor age of human diploid cells in culture. Exp Cell Res 1974;84:363-6.
22. Reinartz J, Batria R, Boukamp P, Fusenig N, Dramer MD. Binding and activation of plasminogen at the surface of human keratinocytes. Exp Cell Res 1993;208:197-208.
23. Stanulis-Praeger B. Cellular senescence revisited: a review. Mech Ageing Dev 1997;38:1-48.
24. Dimri GP, Nakanishi M, Desprez PY, Smith JR, Campisi J. Inhibition of E2F activity by the p21 inhibitor of cyclin-dependent protein kinases in cells expressing or lacking a functional retinoblastoma protein. Mol Cell Biol 1995;16:2987-97.
25. Millis AJ, Hoyle M, McCure HM, Martini H. Differential expression of metalloproteinase genes in aged human fibroblasts. Exp Cell Res 1992;201:373-9.
26. West MD, Pereira-Smith OM, Smith JR. Replicative senescence of human skin fibroblasts correlates with loss of regulation and overexpression of collagenase activity. Exp Cell Res 1989;184:138-47.
27. Wick M, Burger C, Brusselbach S, Lucibello FC, Muller R. A novel member of human tissue inhibitor of metalloproteinases (TIMP) gene family is regulated during G1 progression, mitotic stimulation, differentiation and senescence. J Biol Chem 1994;269:18953-60.
28. West MD. The cellular and molecular biology of skin aging. Arch Dermatol 1994;130:87-95.
29. Laiho M, Saksela O, Andreasen PA, Keski-Oja J. Enhanced production and extra cellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor beta. J Cell Biol 1994;103:2403-10.
30. Overall CM, Wrana JL, Sodek J. Independent regulation of collagenase, 72kDa progelatinase and metalloproteinase inhibitor expression in human fibroblasts by transforming growth factor-β. J Biol Chem 1989;264:1860-9.
31. West MD, Shay JW, Wright WE, Linskens MHK. Altered expression of plasminogen activator and plasminogen activator inhibitor during cellular senescence. Exp Gerontol 1996;31:175-93.
32. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1996;41:4629-36.
33. Werb Z, Mainardi CL, Vater CA, Harris ED. Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med 1977;296:1017-23.
34. Kim BC, Kim HT, Park SH, Cha JS, Yufit T, Kim SJ, Falanga V. Fibroblasts from chronic wounds show altered TGF-β signaling and decreased TGF-β type II receptor expression. J Cell Physiol 2003;195:331-6.
35. Zeng G, McCue HM, Mastrangelo L, Millis JT. Endogenous TGF-B activity is modified during cellular aging. Effects on metalloproteinase and TIMP-1 expression. Exp Cell Res 1996;228:271-6.
36. He CJ, Rebibou JM, Peraldi MN, Meulder Q, Rondeau E. Growth factor-like effect of urokinase type plasminogen activator in human renal cells. Biochem Biophys Res Comm 1991;176:1408-16.